[Antineoplastic effects and mechanism of action of IFN-alpha on brain tumors with use of fluorescent isothiocyanate-labelled IFN].
The antineoplastic effects and mechanism of IFN-alpha with a newly designed fluorescent isothiocyanate-labelled IFN-alpha were studied on three established glioma-cell lines and cultured cells of clinical brain tumors. Viability, cell cycle and cells showing positive reaction with fluorescent isothiocyanate-labelled IFN were analyzed by flow cytometry. U373MG glioma cells in contact with 10(4) IU/ml of IFN for 24 hours had a dose dependency, decreased viability, S-phase block in the cell cycle and high rate of positive reaction with fluorescent isothiocyanate-labelled IFN. Two surgical cases, except for one case, showed similar results and other cell lines or meningiomas were not affected by IFN. As the antineoplastic effects of IFN-alpha correlated with the rate of occurrence of positive cells with fluorescent isothiocyanate-labelled IFN, sensitive tumor cells may have a respective specific receptor for IFN-alpha, and, therefore, fluorescent isothiocyanate-labelled IFN-alpha might be of clinical value with regard to the problem of the receptor as well as sensitivity test.
D000236:Adenoma / Q000473:pathology / Q000628:therapy; D001932:Brain Neoplasms / Q000473:pathology / Q000628:therapy*; D002453:Cell Cycle; D002460:Cell Line; D002478:Cells, Cultured; D005434:Flow Cytometry; D005453:Fluorescence; D005910:Glioma / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007370:Interferon Type I / Q000627:therapeutic use*; D017879:Isothiocyanates; D008579:Meningioma / Q000473:pathology / Q000628:therapy; D010911:Pituitary Neoplasms / Q000473:pathology / Q000628:therapy; D013861:Thiocyanates
D007370:Interferon Type I; D017879:Isothiocyanates; D013861:Thiocyanates; C037152:isothiocyanic acid